ISSN 1725-2423

Official Journal

of the European Union

C 99

Volume 46

25 April 2003

English edition

Information and Notices

Notice No | Contents | Page

Notice to readers (see page 12)

[1] Text with EEA relevance

I

(Information)

COMMISSION

Euro exchange rates [1]

24 April 2003

(2003/C 99/01)

1 euro =

	Currency	Exchange rate		Currency	Exchange rate
USD	US dollar	1,1008	LVL	Latvian lats	0,6343
JPY	Japanese yen	132,03	MTL	Maltese lira	0,4251
DKK	Danish krone	7,4247	PLN	Polish zloty	4,297
GBP	Pound sterling	0,6915	ROL	Romanian leu	36 635
SEK	Swedish krona	9,1102	SIT	Slovenian tolar	232,2565
CHF	Swiss franc	1,5055	SKK	Slovak koruna	40,964
ISK	Iceland króna	83,33	TRL	Turkish lira	1 756 000
NOK	Norwegian krone	7,831	AUD	Australian dollar	1,7819
BGN	Bulgarian lev	1,9461	CAD	Canadian dollar	1,6112
CYP	Cyprus pound	0,58813	HKD	Hong Kong dollar	8,5858
CZK	Czech koruna	31,717	NZD	New Zealand dollar	1,9877
EEK	Estonian kroon	15,6466	SGD	Singapore dollar	1,9567
HUF	Hungarian forint	245,81	KRW	South Korean won	1 343,53
LTL	Lithuanian litas	3,4533	ZAR	South African rand	8,0279

[1] *Source:* reference exchange rate published by the ECB.

Publication of a request under Article 9 of Regulation (EEC) No 2081/92 to amend one or more parts of the specification of a name registered under Article 17 or Article 6 of that Regulation

(2003/C 99/02)

Publication confers the right to object within the meaning of Article 7 of the Regulation. Any objections to this request must be forwarded via the competent authority of a Member State within six months of the publication date.

The amendment is not a minor one and it must therefore be published under Article 6(2) of the Regulation.

COUNCIL REGULATION (EEC) No 2081/92

APPLICATION TO AMEND A SPECIFICATION: ARTICLE 9

1. **Registered name:** Scotch Beef

2. **Responsible department in the Member State:**

Department for Environment, Food and Rural Affairs
Agrifood Exports and Regional Food Promotion Division
Regional and Local Foods Branch
Room 407
Nobel House, 17 Smith Square
London, SW1P 3JR
United Kingdom
Tel. (44-207) 238 66 87
Fax (44-207) 238 56 71

3. **Amendments requested:**

— ***Specification heading(s):***

	name
x	description
	geographical area
	proof of origin
x	method of production
	link
	labelling
	national requirements

— ***Amendment(s):***

Description

In order to better reflect current practice, take account of consumer concerns about greater transparency in labelling and improve the quality of Scotch Beef the current description,

'The product is derived from cattle finished, for a minimum period of 3 months, slaughtered and dressed in the designated area.'

is being amended to the following:

'The product is derived from cattle born, reared for the entirety of their lives, slaughtered and dressed in the designated geographical area. The animals will have been produced and slaughtered in accordance with Quality Assurance schemes accredited to European Standard EN45011 (ISO Guide 65) and having the same standards and assessments and assessment frequencies of those set by the applicant.'

Method of production

As a result of the amendment to the description described above it is necessary to amend the details of the method of production. In addition, when the original application was put forward there was almost no Scotch Beef sold in a frozen state. While this practice is still not widespread, the applicant would like to remove the words 'Only fresh or chilled product may be sold' to allow Scotch Beef to be sold frozen if a processor so wishes.

Therefore the current description,

'Cattle are finished in Scotland for a period of not less than three months. The cattle are slaughtered and dressed in accordance with the set specifications. Only fresh or chilled product may be sold.'

is being amended to the following:

'Cattle are born and reared for the entirety of their lives in the designated geographical area. The animals will have been produced and slaughtered in accordance with Quality Assurance schemes accredited to European Standard EN45011 (ISO Guide 65) and having the same standards and assessments and assessment frequencies of those set by the applicant. They are slaughtered and dressed in that area in accordance with the set specifications.'

Publication of a request under Article 9 of Regulation (EEC) No 2081/92 to amend one or more parts of the specification of a name registered under Article 17 or Article 6 of that Regulation

(2003/C 99/03)

Publication confers the right to object within the meaning of Article 7 of the Regulation. Any objections to this request must be forwarded via the competent authority of a Member State within six months of the publication date.

The amendment is not a minor one and it must therefore be published under Article 6(2) of the Regulation.

COUNCIL REGULATION (EEC) No 2081/92

APPLICATION TO AMEND A SPECIFICATION: ARTICLE 9

1. **Registered name:** Scotch Lamb

2. **Responsible department in the Member State:**

Department for Environment, Food and Rural Affairs
Agrifood Exports and Regional Food Promotion Division
Regional and Local Foods Branch
Room 407
Nobel House, 17 Smith Square
London, SW1P 3JR
United Kingdom
Tel. (44-207) 238 66 87
Fax (44-207) 238 56 71

3. **Amendment(s) requested:**

— ***Specification heading(s):***

	name
x	description
	geographical area
	proof of origin
x	method of production
	link
	labelling
	national requirements

— ***Amendment(s):***

Description

In order to better reflect current practice, take account of consumer concerns about greater transparency in labelling and improve the quality of Scotch Lamb the current description,

'The product is derived from lambs finished, for a minimum period of two months, slaughtered and dressed in the designated area.'

is being amended to the following:

'The product is derived from lambs born, reared for the entirety of their lives, slaughtered and dressed in the designated geographical area. The animals will have been produced and slaughtered in accordance with Quality Assurance schemes accredited to European Standard EN45011 (ISO Guide 65) and having the same standards and assessments and assessment frequencies of those set by the applicant.'

Method of production

As a result of the amendment to the description described above it is necessary to amend the details of the method of production. In addition, when the original application was put forward there was almost no Scotch Lamb sold in a frozen state. While this practice is still not widespread, the applicant would like to remove the words 'Only fresh or chilled product may be sold' to allow Scotch Lamb to be sold frozen if a processor so wishes.

Therefore the current description,

'Lambs are finished in Scotland for a minimum of two months. They are slaughtered and dressed in accordance with set specifications. The lamb is sold fresh or chilled.'

is being amended to the following:

'Lambs are born and reared for the entirety of their lives in the designated geographical area. The animals will have been produced and slaughtered in accordance with Quality Assurance schemes accredited to European Standard EN45011 (ISO Guide 65) and having the same standards and assessments and assessment frequencies of those set by the applicant. They are slaughtered and dressed in that area in accordance with the set specifications.'

Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 March 2003 to 15 April 2003

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 ([1]))

(2003/C 99/04)

— Issuing of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93): accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	No of the entry in the Community Register	Date of notification
24.3.2003	Ytracis	CIS bio international Boîte postale 32 F-91192 Gif-sur-Yvette	EU/1/03/250/001	27.3.2003
27.3.2003	Bextra	Pharmacia-Pfizer EEIG Hillbottom Road High Wycombe Buckinghamshire HP12 4PX United Kingdom	EU/1/02/239/001-024	31.3.2003
27.3.2003	Kudeq	Pfizer Limited Sandwich Kent CT13 9NJ United Kingdom	EU/1/02/244/001-024	31.3.2003
27.3.2003	Valdyn	Pharmacia Europe EEIG Hillbottom Road High Wycombe Buckinghamshire HP12 4PX United Kingdom	EU/1/02/242/001-024	31.3.2003

— Modification of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93): accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	No of the entry in the Community Register	Date of notification
27.2.2003	Aranesp	Amgen Europe BV Minervum 7061 4817 ZK Breda Nederland	EU/1/01/185/001-032	24.3.2003
27.2.2003	Nespo	Dompé Biotec SpA Via San Martino, 12 I-20122 Milano	EU/1/01/184/001-032	24.3.2003
17.3.2003	Optison	Amersham Health AS Nycoveien 1-2 PO Box 4220 Nydalen N-0401 Oslo	EU/1/98/065/001-002	19.3.2003
17.3.2003	Actos	Takeda Europe R & D Centre Ltd Savanah House, 11/12 Charles II Street London SW1Y 4QU United Kingdom	EU/1/00/150/001-010	19.3.2003

([1]) OJ L 214, 24.8.1993, p. 1.

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	No of the entry in the Community Register	Date of notification
17.3.2003	Glustin	Takeda Europe R & D Centre Ltd Savanah House, 11/12 Charles II Street London SW1Y 4QU United Kingdom	EU/1/00/151/001-008	19.3.2003
17.3.2003	Sonata	Wyeth Europa Limited Huntercombe Lane South Taplow Maidenhead Berkshire SL6 0PH United Kingdom	EU/1/99/102/001-008	19.3.2003
17.3.2003	ViraferonPeg	Schering Plough Europe Rue de Stalle, 73 B-1180 Bruxelles	EU/1/00/132/001-050	19.3.2003
17.3.2003	Pegintron	Schering Plough Europe Rue de Stalle, 73 B-1180 Bruxelles	EU/1/00/131/001-050	19.3.2003
17.3.2003	Caelyx	Schering Plough Europe Rue de Stalle, 73 B-1180 Bruxelles	EU/1/96/011/001-004	19.3.2003
17.3.2003	Zerene	Wyeth Research (UK) Limited Huntercombe Lane South Taplow Maidenhead Berkshire SL6 0PH United Kingdom	EU/1/99/099/001-006	19.3.2003
17.3.2003	Vistide	Pharmacia Enterprises SA 6, Circuit de la Foire Internationale BP 2507 L-1347 Luxembourg	EU/1/97/037/001	19.3.2003
17.3.2003	NeoRecormon	Roche Registration Limited 40 Broadwater Road Welwyn Garden City Hertfordshire AL7 3AY United Kingdom	EU/1/97/031/001-013, EU/1/97/031/019-044	19.3.2003
17.3.2003	Ovitrelle	Serono Europe Limited 56, Marsh Wall London E14 9TP United Kingdom	EU/1/00/165/001-006	19.3.2003
17.3.2003	Neoclarityn	Schering Plough Europe Rue de Stalle, 73 B-1180 Bruxelles	EU/1/00/161/001-034	19.3.2003
17.3.2003	Aerius	Schering Plough Europe Rue de Stalle, 73 B-1180 Bruxelles	EU/1/00/160/001-034	19.3.2003

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	No of the entry in the Community Register	Date of notification
17.3.2003	Azomyr	Schering Plough Europe Rue de Stalle, 73 B-1180 Bruxelles	EU/1/00/157/001-034	19.3.2003
17.3.2003	Allex	Schering Plough Europe Rue de Stalle, 73 B-1180 Bruxelles	EU/1/00/159/001-034	19.3.2003
17.3.2003	Opulis	Schering Plough Europe Rue de Stalle, 73 B-1180 Bruxelles	EU/1/00/158/001-034	19.3.2003
17.3.2003	Quadramet	CIS bio international Boîte postale 32 F-91192 Gif-sur-Yvette	EU/1/97/057/001	20.3.2003
20.3.2003	Arixtra	Sanofi-Synthelabo 174, avenue de France F-75013 Paris	EU/1/02/206/001-004	24.3.2003
20.3.2003	Quixidar	NV Organon PO Box 20 Kloosterstraat 6 5340 EB Oss Nederland	EU/1/02/207/001-004	24.3.2003
20.3.2003	Iscover	Bristol-Myers Squibb Pharma EEIG 141-149 Staines Road Hounslow TW3 3JA United Kingdom	EU/1/98/070/004a-004b	24.3.2003
24.3.2003	Liprolog	Eli Lilly Nederland BV Grootslag 1-5 3991 RA Houten Nederland	EU/1/01/195/001-015	27.3.2003
24.3.2003	Zometa	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	EU/1/01/176/004-006	27.3.2003
24.3.2003	Plavix	Sanofi Pharma Bristol-Myers Squibb SNC 174, avenue de France F-75013 Paris	EU/1/98/069/004a-004b	27.3.2003
24.3.2003	Integrelin	Schering Plough Europe Rue de Stalle, 73 B-1180 Bruxelles	EU/1/99/109/001-002	27.3.2003
24.3.2003	Gonal-f	Serono Europe Limited 56, Marsh Wall London E14 9TP United Kingdom	EU/1/95/001/001-031	27.3.2003

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	No of the entry in the Community Register	Date of notification
24.3.2003	SonoVue	Bracco International BV Strawinskylaan 3051 1077ZX Amsterdam Nederland	EU/1/01/177/001-002	27.3.2003
24.3.2003	Agenerase	Glaxo Group Ltd Greenford Middlesex UB6 0NN United Kingdom	EU/1/00/148/001-004	27.3.2003
27.3.2003	Viread	Gilead Sciences International Limited Cambridge CB1 6 GT United Kingdom	EU/1/01/200/001	31.3.2003
8.4.2003	Xapit	Pharmacia Europe EEIG Hillbottom Road High Wycombe Buckinghamshire HP12 4PX United Kingdom	EU/1/02/208/001-008	10.4.2003
8.4.2003	Ziagen	Glaxo Group Ltd Greenford Middlesex UB6 0NN United Kingdom	EU/1/99/112/002	10.4.2003
8.4.2003	Fabrazyme	Genzyme Europe BV Gooimeer 10 Naarden 1411 DD Nederland	EU/1/01/188/001-006	10.4.2003
8.4.2003	Osigraft	Howmedica International S. de R.L. Division of Stryker Corporation Raheen Industrial Estate Raheen Limerick Ireland	EU/1/01/179/001	14.4.2003
8.4.2003	MabCampath	ILEX Pharmaceutical Ltd 1 & 3 Frederick Sanger Road The Surrey Research Park Guildford Surrey GU2 7YD United Kingdom	EU/1/01/193/001	10.4.2003
9.4.2003	Opatanol	Alcon Laboratories (UK) Ltd Pentagon Park Boundary Way Hemel Hempstead Herts HP2 7UD United Kingdom	EU/1/02/217/001-002	11.4.2003

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	No of the entry in the Community Register	Date of notification
9.4.2003	Rayzon	Pharmacia Europe EEIG Hillbottom Road High Wycombe Buckinghamshire HP12 4PX United Kingdom	EU/1/02/210/001-008	11.4.2003
9.4.2003	Dynastat	Pharmacia Europe EEIG Hillbottom Road High Wycombe Buckinghamshire HP12 4PX United Kingdom	EU/1/02/209/001-008	11.4.2003
9.4.2003	Daquiran	Dr. Karl Thomae GmbH Birkendorfferstraße 65 D-88397 Biberach/Riss	EU/1/97/052/001-006, EU/1/97/052/009-010	11.4.2003
9.4.2003	Cancidas	Merck Sharp & Dohme Ltd Hertford Road Hoddesdon Hertfordshire EN11 9BU United Kingdom	EU/1/01/196/001-003	11.4.2003
10.4.2003	Ferriprox	Apotex Europe Ltd Rowan House 41 London Street Reading Berkshire RG1 4PS United Kingdom	EU/1/99/108/001	15.4.2003
10.4.2003	Infergen	Yamanouchi Europe BV Elisabethhof 19 2353 EW Leiderdorp Nederland	EU/1/98/087/001-003	15.4.2003
10.4.2003	Panretin	Ligand Pharmaceuticals UK Ltd Innovis House 108 High Street Crawley West Sussex RH10 1BB United Kingdom	EU/1/00/149/001	15.4.2003

— **Withdrawal of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93)**

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	No of the entry in the Community Register	Date of notification
17.3.2003	Olansek	Eli Lilly UK Ltd Kingsclere Road Basingstoke Hampshire United Kingdom	EU/1/96/021/001-010	19.3.2003

— **Issuing of a marketing authorisation (Article 34 of Council Regulation (EEC) No 2309/93): accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	No of the entry in the Community Register	Date of notification
2.4.2003	Advocate	Bayer AG D-51368 Leverkusen	EU/2/03/039/001-012	4.4.2003

— **Modification of a marketing authorisation (Article 34 of Council Regulation (EEC) No 2309/93): accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	No of the entry in the Community Register	Date of notification
17.3.2003	Fevaxyn Pentofel	Fort Dodge Laboratories Ireland Finisklin Industrial Estate Sligo Ireland	EU/2/96/002/001-003	19.3.2003
17.3.2003	Metacam	Boehringer Ingelheim Vetmedica GmbH D-55216 Ingelheim am Rhein	EU/2/97/004/001, EU/2/97/004/003-008	19.3.2003
20.3.2003	Ibaflin	Intervet International BV Wim de Körverstraat 35 5831 AN Boxmeer Nederland	EU/2/00/022/009-012	24.3.2003
9.4.2003	Nobivac Bb	Intervet International BV Wim de Körverstraat 35 5831 AN Boxmeer Nederland	EU/2/02/034/001	11.4.2003
9.4.2003	Bayovac CSF E2	Bayer AG Geschäftsbereich Tiergesundheit D-51368 Leverkusen	EU/2/00/025/001-004	11.4.2003

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Agency for the Evaluation of Medicinal products
7 Westferry Circus,
Canary Wharf
London E14 4HB
United Kingdom.

Prior notification of a concentration

(Case COMP/M.3108 — Office Depot/Guilbert)

(2003/C 99/05)

(Text with EEA relevance)

1. On 15 April 2003 the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EEC) No 4064/89 [1], as last amended by Regulation (EC) No 1310/97 [2], by which the undertaking Office Depot Inc., (Office Depot), United States of America, acquires, within the meaning of Article 3(1)(b) of the Regulation, control of the whole of the undertaking Guilbert SA (Guilbert), France, by way of purchase of shares.

2. The business activities of the undertakings concerned are:

— Office Depot: distribution on a worldwide basis of office and furniture supplies to small offices/home offices, medium-sized and large businesses through various channels, including retail superstores, contract sales force, Internet and mail order,

— Guilbert: distribution of office and furniture supplies to large and medium-sized companies in the EEA through contract sales force. Guilbert is part of the Pinault-Printemps-Redoute Group.

3. On preliminary examination, the Commission finds that the notified concentration could fall within the scope of Regulation (EEC) No 4064/89. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent by fax (No (32-2) 296 43 01 or 296 72 44) or by post, under reference COMP/M.3108 — Office Depot/Guilbert, to:

European Commission,
Directorate-General for Competition,
Directorate B — Merger Task Force,
J-70,
B-1049 Brussels.

---

[1] OJ L 395, 30.12.1989, p. 1; Corrigendum: OJ L 257, 21.9.1990, p. 13.

[2] OJ L 180, 9.7.1997, p. 1; Corrigendum: OJ L 40, 13.2.1998, p. 17.

Freedom – Security – Justice
Building Europe without borders

Directorate-General
for Justice and Home Affairs

Follow step by step…
Each day, thanks to our work and yours, Europe is growing and prospering as an area of freedom, security and justice for all.
To bring us even closer together, to respond more effectively to all your queries and to enable you to follow our common evolution, the new website *Freedom - Security - Justice* is a source of information you should consult. The site, built by the European Commission's Directorate-General for Justice and Home Affairs, offers you a unique tool to navigate through the teeming European debate and follow each step in the construction of the new area of freedom, security and justice.

… the construction of Europe.
A wealth of information, from the general to the specific, is at your fingertips thanks to the site's simple navigation. It is organised into 13 major chapters:

- Asylum
- Immigration
- Police
- Customs
- Crime
- Drugs
- Civil law
- Criminal law
- Fundamental rights
- Citizenship
- Free movement
- Foreign affairs
- Enlargement

Cross the threshold of tomorrow's Europe and see how our common area of freedom, security and justice will look.

http://europa.eu.int/comm/justice_home/

Making the European Union into a place of freedom, security and justice.

European Commission